DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Debiec-Rychter M, Sciot R, Verweij J, Casali P, LeCesne A, Zalcberg J, Hohenberger P, Blay JY, Schlemmer M, VanGlabbeke M. et al.
KIT mutations should guide dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Results of mutation analysis in 377 patients entered into a randomized study.
Nature Med ; : (submitted)-
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.